Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESRRB | O95718 | 1/20 | 0.55 |
| ▸ | ESR1 | P03372 | 1/20 | 0.55 |
| ▸ | ESRRA | P11474 | 1/20 | 0.55 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.55 |
| ▸ | DHODH | Q02127 | 6/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1343029 | 0.85 | ESR1 (0.58) | ESRRBESR1ESRRAESR2DHODH | |
| SCHEMBL19919243 | 0.84 | ESR1 (0.52) | ESRRBESR1ESRRAESR2DHODH | |
| SCHEMBL2186392 | 0.82 | XDH (0.55) | ESRRBESR1ESRRAESR2DHODH | |
| SCHEMBL8689228 | 0.80 | DHODH (0.82) | DHODHKDM4EPDE10ALMNASMN1; SMN2 | |
| SCHEMBL29893710 | 0.79 | ESR1 (0.47) | ESRRBESR1ESRRAESR2POLB | |
| SCHEMBL2185509 | 0.77 | ESR1 (0.50) | ESR1ESR2 | |
| SCHEMBL24795633 | 0.75 | ESR1 (0.48) | ESRRBESR1ESRRAESR2KDM4E | |
| SCHEMBL1897930 | 0.75 | DHODH (0.74) | DHODHKDM4EPDE10ALMNASMN1; SMN2 | |
| SCHEMBL19919269 | 0.75 | ESR1 (0.45) | ESRRBESR1ESRRAESR2DHODH | |
| SCHEMBL2189466 | 0.74 | DHODH (0.55) | ESRRBESR1ESRRAESR2DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2343279-B1 | FUSED-RING DERIVATIVE AND MEDICAL APPLICATION OF SAME | KISSEI PHARMACEUTICAL (JP) | 2018-02-28 | — | — | EP | disclosed |
| CN-102186824-B | Fused-ring derivative and medical application of same | KISSEI PHARMACEUTICAL | 2014-03-12 | — | — | CN | disclosed |
| US-8263622-B2 | Fused-ring derivative and medical application of same | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-09-11 | — | — | US | disclosed |
| US-8263622-B2 | Fused-ring derivative and medical application of same | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-09-11 | — | — | US | disclosed |
| US-8263622-B2 | Fused-ring derivative and medical application of same | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-09-11 | — | — | US | disclosed |
| CN-102186824-A | Fused-ring derivative and medical application of same | KISSEI PHARMACEUTICAL | 2011-09-14 | — | — | CN | disclosed |
| US-20110207935-A1 | FUSED-RING DERIVATIVE AND MEDICAL APPLICATION OF SAME | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2011-08-25 | — | — | US | disclosed |
| US-20110207935-A1 | FUSED-RING DERIVATIVE AND MEDICAL APPLICATION OF SAME | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2011-08-25 | — | — | US | disclosed |
| US-20110207935-A1 | FUSED-RING DERIVATIVE AND MEDICAL APPLICATION OF SAME | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2011-08-25 | — | — | US | disclosed |
| EP-2343279-A1 | FUSED-RING DERIVATIVE AND MEDICAL APPLICATION OF SAME | Kissei Pharmaceutical Co., Ltd. (JP) | 2011-07-13 | — | — | EP | disclosed |
| EP-2343279-A1 | FUSED-RING DERIVATIVE AND MEDICAL APPLICATION OF SAME | Kissei Pharmaceutical Co., Ltd. (JP) | 2011-07-13 | — | — | EP | disclosed |
| WO-2010044405-A1 | FUSED-RING DERIVATIVE AND MEDICAL APPLICATION OF SAME | キッセイ薬品工業株式会社 (JP) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207935-A1 | FUSED-RING DERIVATIVE AND MEDICAL APPLICATION OF SAME | XDH, OAT, PON1 | ESRRB 1810/4885ESR1 3404/4885ESRRA 1727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.